Minireview
General pharmaceutics—The new physical pharmacy
Article first published online: 17 APR 2003
DOI: 10.1002/jps.10366
Copyright © 2003 Wiley-Liss, Inc.
Additional Information
How to Cite
Fiese, E. F. “. (2003), General pharmaceutics—The new physical pharmacy. Journal of Pharmaceutical Sciences, 92: 1331–1342. doi: 10.1002/jps.10366
Publication History
- Issue published online: 17 APR 2003
- Article first published online: 17 APR 2003
- Manuscript Accepted: 15 NOV 2002
- Manuscript Revised: 30 OCT 2002
- Manuscript Received: 29 JUL 2002
- Abstract
- Article
- References
- Cited By
Keywords:
- crystallinity;
- polymorph;
- solubility;
- stability;
- absorption;
- particle size;
- profiles
Abstract
General Pharmaceutics is proposed as the broad study of the biopharmaceutical and physical chemical properties of each potential drug substance. When the first quality bulk lot is delivered, usually the first GMP bulk lot, an extensive profiling of the potential drug substance should commence. This profile should include solid-state characterization as well as thorough analyses of solubility, stability, and absorption properties of the drug substance that could affect the development of a viable medicine. As a result of these studies, a number of initial specifications could be developed: the preferred polymorphic or crystalline form identified, the preferred particle size to optimize absorption/development, and an initial biopharmaceutics classification with a dose limit to identify those cases in which the formulation can be expected to improve absorption and exposure. The broad topic of General Pharmaceutics is discussed in this Minireview including many advances in technology in this field as well as the rationale behind the proposed initial specifications. © 2003 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 92:1331–1342, 2003

1520-6017/asset/JPS_left.gif?v=1&s=becd26fac43b87042ad04af68bbe20d6a12e64fc)
1520-6017/asset/olbannerright.jpg?v=1&s=254f44b422de0f476861bd1056a1789033e2171c)
1520-6017/asset/cover.gif?v=1&s=e589ccf35fd012c675e943835781318cb8666bed)